Formulation Design of a Highly Hygroscopic Drug (Pyridostigmine Bromide) for its Hygroscopic Character Improvement and Investigation of In Vitro/In Vivo Dissolution Properties

REFERENCES

• Baert L., Remon J. P. Influence of amount of granulation liquid on the drug release rate from pellets made by extrusion spheronisation. Int. J. Pharm. 1993; 95(1–3)135–141
   Google Scholar
• Bechgaard H., Hegermann‐Nielsen G. Controlled release multiple units and single‐unit doses. Drug Dev. Ind. Pharm. 1978; 4(1)53–67
   Web of Science ®Google Scholar
• Bodea A., Leucuta S. E. Optimization of propranolol hydrochloride sustained release pellets using a factorial design. Int. J. Pharm. 1997; 154(1)49–57
   Google Scholar
• Chariot M., Francès J., Lewis G. A., Mathieu D., Phan Tan Luu R., Stevens H. N. E. A factorial approach to process variables of extrusion-spheronisation of wet powder masses. Drug Dev. Ind. Pharm. 1987; 13(9–11)1639–1649
   Web of Science ®Google Scholar
• Conine J. W., Hadley H. R. Preparation of small solid pharmaceutical spheres. Drug Cosmet. Ind. 1970; 106(1)38–41
   Google Scholar
• Dirnhuber P., Green D. M. Effectiveness of Pyridostigmine in Reversing the Neuromuscular Blockade Produced by Soman. J. Pharm. Pharmacol. 1978; 30(7)419–425
   PubMed Web of Science ®Google Scholar
• Engineer S., Shao Z. J., Khagani N. A. Temperature/humidity sensitivity of sustained-release formulations containing Kollidon®SR. Drug Dev. Ind. Pharm. 2004; 30(10)1089–1094
   PubMed Web of Science ®Google Scholar
• Gandhi R., Kaul C. L., Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm. Sci. Technol. Today. 1999; 2(1)60–170
   PubMedGoogle Scholar
• Hegazy N., Demirel M., Yazan Y. Preparation and in vitro evaluation of pyridostigmine bromide microparticles. Int. J. Pharm. 2002; 242(1–2)171–174
   PubMed Web of Science ®Google Scholar
• Hileman G. A., Goskonda S. R., Spalitto A. J., Upadrashta S. M. A factorial approach to high dose product development by an extrusion/spheronization process. Drug Dev. Ind. Pharm. 1993; 19(4)483–491
   Web of Science ®Google Scholar
• Huang Y. B., Tsai Y. H., Yang W. C., Chang J. S., Wu P. C., Takayama K. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur. J. Pharm. Biopharm. 2004; 58(3)607–614
   PubMed Web of Science ®Google Scholar
• Kang H. K., Bullman T. A., Macfarlane G. J., Gray G. C. Mortality among US and UK veterans of the Persian Gulf War: a review. Occup. Environ. Med. 2002; 59(12)794–799
   PubMed Web of Science ®Google Scholar
• Korsmeyer R. W., Gurny R., Doelker E., Buri P., Peppas N. A. Mechanisms of solute release from porous hydrophilic polymer. Int. J. Pharm. 1983; 15(1)25–35
   Web of Science ®Google Scholar
• Li S., Lin S., Daggy B. P., Mirchandani H. L., Chien Y. W. Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Dev. Ind. Pharm. 2002; 28(7)783–793
   PubMed Web of Science ®Google Scholar
• Li S., Lin S., Daggy B. P., Mirchandani H. L., Chien Y. W. Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int. J. Pharm. 2003; 253(1–2)13–22
   PubMedGoogle Scholar
• Lin A. Y., Muhammad N. A., Pope D., Augsburger L. L. A study of the effects of curing and storage conditions on controlled release diphenhydramine HCl pellets coated with Eudragit® NE30D. Pharm. Dev. Tech. 2003; 8(3)277–287
   PubMed Web of Science ®Google Scholar
• Lövgren K., Lundberg P. J. Determination of sphericity of pellets prepared by extrusion/spheronization and the impact of some process parameters. Drug Dev. Ind. Pharm. 1989; 15(14–16)2375–2392
   Web of Science ®Google Scholar
• Martin A., Bustamante P., Chun A. Chapter 16 Micromeritics. Physical Pharmacy. Lea and Febiger, London 1993; 423–452
   Google Scholar
• Michaelis H. C. Determination of pyridostigmine plasma concentrations by high-performance liquid chromatography. J. Chromatogr. 1990; 534(1)291–294
   PubMed Web of Science ®Google Scholar
• Montgomery D. C. Design and Analysis of Experiments. John Wiley & Sons, New York, NY 1996
   Google Scholar
• Paterakis P. G., Korakianiti E. S., Dallas P. P., Rekkas D. M. Evaluation and simultaneous optimization of some pellets characteristics using a 33 factorial design and the desirability function. Int. J. Pharm. 2002; 248(1–2)51–60
   PubMed Web of Science ®Google Scholar
• Peppas N. A., Sahlin J. J. A simple equation for the description of solute release, III. Coupling of diffusion and relaxation. Int. J. Pharm. 1989; 57(2)169–172
   Web of Science ®Google Scholar
• Porter S. C. Use of opadry, sureteric, and surelease for the aqueous film coating of pharmaceutical oral dosage forms. Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, J. W. McGinity. Marcel Dekker, Inc., New York 1997; 327–372
   Google Scholar
• Qiu Y., Cheskin H. S., Engh K. R., Poska R. P. Once-a-day controlled release dosage form of divalproex sodum I: formulation design and in vitro/in vivo investigations. J. Pharm. Sci. 2003; 92(6)1166–1173
   PubMed Web of Science ®Google Scholar
• Ragnarsoson G., Johansson M. O. Coated drug cores in multiple unit preparation-Influence of particle size. Drug Dev. Ind. Pharm. 1988; 14(15–17)2285–2297
   Web of Science ®Google Scholar
• Rambali B., Baert L., Thonè D., Massart D. L. Using experimental design to optimize the process parameters in fluidized bed granulation. Drug Dev. Ind. Pharm. 2001; 27(1)47–55
   PubMed Web of Science ®Google Scholar
• Reynold A. D. A new technique for the production of spherical particles. Mfg. Chem. Aerosol. News. 1970; 41(1)40–43
   Google Scholar
• Ritger P. L., Peppas N. A. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinder or discs. J. Control. Release. 1987a; 5(1)23–36
   Google Scholar
• Ritger P. L., Peppas N. A. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control. Release. 1987b; 5(1)37–42
   Google Scholar
• Roshdy M. N., Schnaare R. L., Sugita E. T., Schwartz J. B. The effect of controlled release tablet performance and hydrogel strength on in vitro/in vivo correlation. Pharm. Dev. Tech. 2002; 7(2)155–168
   PubMed Web of Science ®Google Scholar
• Sidell F. R. Nerve agents, Part I: Medical aspects of chemical and biological warfare. The Textbooks of Military Medicine, F. R. Sidell, E. T. Takafuji, D. R. Franz. Office of the Surgeon General Department of the Army, Washington, D. C. USA. 1997; 129–179
   Google Scholar
• Takka S., Sakr A., Goldberg A. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J. Control. Release. 2003; 88(1)147–157
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration (FDA). Guidance for industry, dissolution testing of IR solid oral dosage forms. 1997
   Google Scholar
• United States Food and Drug Administration (FDA). FDA approves PB as pretreatment against nerve gas. 2003
   Google Scholar
• Vervaet C., Baert L., Remon J. P. Extrusion-spheronisation a literature review. Int. J. Pharm. 1995; 116(2)131–146
   Web of Science ®Google Scholar
• Wanger J., Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci. 1964; 53(11)1392–1404
   PubMed Web of Science ®Google Scholar
• Yang S. C., Zhu J. B. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev. Ind. Pharm. 2002; 28(3)265–274
   PubMed Web of Science ®Google Scholar
• Zhang G. H., Schwartz J. B., Schnaare R. L. Bead coating. I. Change in release kinetics (and mechanism) due to coating levels. Pharm. Res. 1991; 8(3)331–335
   PubMed Web of Science ®Google Scholar